RECIST y el radiólogo

CT and 18-FDG PET/CT for the assessment of treatment response in Hodgkin’s and Non-Hodgkin lymphoma

“…9,10 Imaging systems play a highly important role in this assessment, since in the works by Barrington, Meignan and Kulkarni, the comparison of imaging studies before and after treatment was shown to be vital in order to not have false positive or false negative results. 16,17,20 Now, for the assessment of response, the imaging specialist of the CT department used a qualitative method in 39 (90.7 %) and a systematized quantitative method (RECIST 1.1) only in four (9.3 %) subjects, which is not in agreement with international guidelines recommendations, which suggest a systematization of tumor assessment supported by a digital imaging system, 11,12,13 in contrast to that which was observed in the doctors of the PET/CT department, who reported their results based on PERCIST or Deauville criteria, which are indicated in Lugano's criteria to assess treatment response. 17 PERCIST criteria were used in 13 cases (30.2 %) and Deauville criteria in 30 (69.8 %), taking into account that the five-point classification is the most commonly used in this department and that it correlates with the National Comprehensive Cancer Network guidelines recommendation.…”

“…9,17 The assessment is based on PERCIST and Deauville criteria, which have as key point the determination of background SUV and its comparison with the lymph nodes that show higher uptake. 13,14 The disadvantage of this method is its poor accessibility in Mexico; however, in international literature, CT is suggested as an alternative method, 18 given the availability of the RECIST 1.1 criteria, which are specific for treatment response assessment according to lymph nodes localization, size and morphology. 19 In this study, the sample was found to have an age and gender distribution similar to those reported in publications of the World Health Organization in patients with lymphoma.…”

“…11,12 Tumor volume measurement is an alternative to unidimensional and two-dimensional measurement procedures, given that a large number of neoplasms are not spherical and grow or shrink irregularly. 13,14 In 1999, the international working group for non-Hodgkin lymphoma therapeutic response assessment standardization established follow-up based on a combination of markers, clinical findings and radiological evaluation by computed tomography (CT) according to two-dimensional size criteria. In 2007, the International Harmonization Project incorporated the use of positron-emission tomography (PET)/CT with 18-FDG and immunohistochemistry criteria for the management of Hodgkin's disease.…”

TAC y PET/TC con 18-FDG para evaluar la respuesta al tratamiento en linfoma de Hodgkin y no Hodgkin

“…11,12 La medición del volumen tumoral es una alternativa a los procedimientos de medición unidimensional y bidimensional, dado que un gran número de neoplasias no son esféricas y crecen o se reducen de forma irregular. 13,14 En 1999, el grupo de trabajo internacional para la normalización de la evaluación de la respuesta terapéutica de los linfomas no Hodgkin estableció el seguimiento basado en la combinación de marcadores, hallazgos clínicos y evaluación radiológica mediante tomografía computarizada según criterios de tamaño bidimensionales. En 2007, el Proyecto de Armonización Internacional incorporó el uso de tomografía por emisión de positrones (PET)/CT con 18-FDG para el manejo de la enfermedad de Hodgkin y criterios de inmunohistoquímica.…”

Tratamiento y resultados del glioblastoma multiforme en nuestro centro. Período 2010-2014

“…Los procedimientos quirúrgicos incluyen la biopsia estereotáxica para la obtención de un diagnóstico anatomopatológico, y la resección quirúrgica que permite un diagnóstico preciso por la cantidad y calidad del tejido tumoral obtenido, mitigar los síntomas neurológicos al disminuir el efecto de masa, citorreducción que permite una mejor respuesta al tratamiento radioterápico, administración de tratamientos locales como los implantes de carmustina, y drenar líquido cefalorraquídeo si fuese preciso. La utilización de carmustina de forma intraoperatoria, ha demostrado un discreto aumento de la supervivencia en estos pacientes, tanto a principio del tratamiento como en caso de recaída (14,15 (18). Se presta especial atención al volumen tumoral y a los cambios metabólicos.…”